Drugs / LY3849891
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05395481 | Jun 2022 → May 2026 | metabolic dysfunction-associated steatohepatitis | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3849891 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05395481 ↗ |
| Route | Subcutaneous | “administered subcutaneously (SC)” NCT05395481 ↗ |